AIM ImmunoTech (NYSEAMERICAN:AIM) Trading Down 2.7% – Should You Sell?

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) fell 2.7% during trading on Thursday . The company traded as low as $0.2150 and last traded at $0.2269. 10,380,839 shares changed hands during mid-day trading, a decline of 9% from the average daily volume of 11,424,733 shares. The stock had previously closed at $0.2332.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets reduced their target price on AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, June 1st. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, AIM ImmunoTech has an average rating of “Moderate Buy” and an average price target of $9.00.

AIM ImmunoTech Price Performance

The stock has a market cap of $6.91 million, a P/E ratio of -0.07 and a beta of 1.19. The company’s 50 day simple moving average is $0.25 and its 200 day simple moving average is $0.45.

AIM ImmunoTech (NYSEAMERICAN:AIM) last posted its earnings results on Friday, August 7th. The company reported ($0.43) earnings per share for the quarter. The business had revenue of $0.03 million for the quarter. On average, equities research analysts predict that AIM ImmunoTech Inc. will post -0.78 earnings per share for the current year.

Institutional Trading of AIM ImmunoTech

An institutional investor recently bought a new stake in AIM ImmunoTech stock. Corient Private Wealth LLC bought a new position in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned approximately 1.31% of AIM ImmunoTech at the end of the most recent quarter. Institutional investors own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.